First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes.
OBJECTIVE
To compare clinical efficacy and safety of stents eluting limus drugs from biodegradable polymer - Nobori, or durable polymer - Cypher.


RESULTS
From May to August 2006, 107 patients with 142 coronary artery lesions were treated with either Nobori, Biolimus A9 eluting stent (54) or Cypher, Sirolimus eluting stent (53) in five centres. The two groups were well matched for baseline clinical and angiographic characteristics. The in-stent late loss at nine months, the primary endpoint of the study, was 0.10+/-0.26 mm in Nobori, and 0.13+/-0.44 mm in Cypher arm (p=0.660) confirming the hypothesis of the similarity between the two stents. In-stent diameter stenosis of 13+/-10% with Nobori was significantly lower than 20+/-12% with Cypher stent (p=0.002) without significant difference in binary restenosis (1.7% in Nobori and 6.3% in Cypher arm; p=0.32). The rate of major adverse cardiac events at 12 months was 1.9% with Nobori and 4.1% with Cypher stent.


CONCLUSIONS
The nine months angiographic data from Nobori Core study demonstrate that Biolimus A9 has similar anti-proliferative efficacy to Sirolimus as judged by in-stent late loss and restenosis rate. Low frequency of adverse cardiac events at 12 months indicates that both stents are safe and effective in the studied population.
Ostojic
Miodrag
M
Clinical Centre of Serbia, Belgrade, Serbia.
Sagic
Dragan
D
Beleslin
Branko
B
Jung
Robert
R
Perisic
Zoran
Z
Jagic
Nikola
N
Nedeljkovic
Milan
M
Mangovski
Ljupco
L
Milosavljevic
Bratislav
B
Stojkovic
Sinisa
S
Orlic
Dejan
D
Antonic
Zelimir
Z
Miloradovic
Vladimir
V
Topic
Dragan
D
Paunovic
Dragica
D